

NKR52_Meniere_PICO 8 Gentamicin

Characteristics of studies

Characteristics of included studies

Postema 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010).</p>

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Allocation concealment (selection bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Blinding of participants and personnel (performance bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Blinding of outcome assessment (detection bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Incomplete outcome data (attrition bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Selective reporting (reporting bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Other bias	High risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>

Stokroos 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010).</p>

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Allocation concealment (selection bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Blinding of participants and personnel (performance bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>
Blinding of outcome assessment (detection bias)	Low risk	<p>For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)</p>

Incomplete outcome data (attrition bias)	High risk	For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)
Selective reporting (reporting bias)	High risk	For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)
Other bias	High risk	For more information see: Pullens, Bas, and Peter Paul van Benthem. "Intratympanic gentamicin for Ménière's disease or syndrome." <i>Cochrane Database of Systematic Reviews</i> 3 (2010)

Footnotes

Characteristics of excluded studies

Casani 2012

Reason for exclusion	Wrong study design
----------------------	--------------------

Jumaily 2017

Reason for exclusion	Wrong intervention
----------------------	--------------------

Patel 2016

Reason for exclusion	Wrong study design
----------------------	--------------------

Sarafraz 2015

Reason for exclusion	Wrong study design
----------------------	--------------------

UI 2017

Reason for exclusion	Wrong study design
----------------------	--------------------

Footnotes

Characteristics of studies awaiting classification

Footnotes

Characteristics of ongoing studies

Footnotes

Summary of findings tables

Additional tables

References to studies

Included studies

Postema 2008

[Empty]

Stokroos 2004

[Empty]

Excluded studies

Casani 2012

[Empty]

Jumaily 2017

[Empty]

Patel 2016

[Empty]

Sarafraz 2015


[Empty]

UI 2017

[Empty]


Studies awaiting classification**Ongoing studies****Other references****Additional references****Other published versions of this review****Classification pending references****Data and analyses****1 Gentamicin vs Placebo**

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Sværhedsgraden af Tinnitus (distribution of tinnitus severity score) 12 mdr efter start af behænding	1	26	Mean Difference (IV, Fixed, 95% CI)	0.10 [-0.48, 0.68]
1.2 Anfaldshyppighed (No. vertiginous attacks per year) 28 mdr efter start af behænding	1	22	Mean Difference (IV, Fixed, 95% CI)	-11.00 [-19.39, -2.61]
1.4 Høretab (Fletcher index) 12 mdr efter start af behænding	2	49	Mean Difference (IV, Random, 95% CI)	3.70 [-8.29, 15.69]
1.5 Sværhedsgraden af vertigo (distribution of vertigo scores) 12 mdr efter start af behænding	1	26	Mean Difference (IV, Fixed, 95% CI)	-1.30 [-1.99, -0.61]
1.6 Aural fullness (distribution of aural fullness) 12 mdr efter start af behænding	1	26	Mean Difference (IV, Fixed, 95% CI)	-0.90 [-1.77, -0.03]

Figures**Figure 1 (Analysis 1.1)****Risk of bias legend**


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Gentamicin vs Placebo, outcome: 1.1 Sværhedsgraden af Tinnitus (distribution of tinnitus severity score) 12 mdr efter start af behænding.

Figure 2 (Analysis 1.2)**Risk of bias legend**


- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Gentamicin vs Placebo, outcome: 1.2 Anfaldshyppighed (No. vertiginous attacks per year) 28 mdr efter start af behænding.

Figure 3 (Analysis 1.4)**Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Gentamicin vs Placebo, outcome: 1.4 Høretab (Fletcher index) 12 mdr efter start af behandling.

Figure 4 (Analysis 1.5)**Risk of bias legend**

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Forest plot of comparison: 1 Gentamicin vs Placebo, outcome: 1.5 Sværhedsgraden af vertigo (distribution of vertigo scores) 12 mdr efter start af behandling.